Product Name: ErbB4 (730-736) pY733
Product Number: PE-04AME99
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: ErbB4 (730-736) pY733

Product Use: Services as a blocking peptide for use with the ErbB4-pY733 rabbit polyclonal antibody (Cat. No.: AB-PK619) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the region between the transmembrane and kinase catalytic domains. The major in vivo site of phosphorylation in ErbB4. Phosphorylation induces interaction with SHC1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: GTV-pY-KGI

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 990.1 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: ErbB4 - pY733 phosphosite-specific antibody (Cat. No.: AB-PK619)

Scientific Background: ErbB4 (HER4) is a protein-tyrosine kinase of the TK group and EGFR family. It is a receptor kinase that upon binding ligands such as neuregulins can drive signalling cascades and many cellular responses to change gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation. Phosphorylation at Y1056 induces interaction with PIK3C2A, and phosphorylation at Y188 induces interaction with Shc1. ErbB4 is a known oncoprotein (OP) and tumour suppressor protein (TSP). Downregulation of ErbB4 has been described in bladder cancer to correlated with oncogensis, but its upregulation is noted in lung cancer. Its mutation pattern in human tumours is very characteristic of a tumour suppressor protein. Mutations in ErbB4 are associated with many types of cancer. Multiple missense mutations in ErbB4 have been found in melanoma patients with increased ErbB4 phosphotransferase activity and transformation ability. Melanoma cells with mutant ErbB4 had reduced cell growth after shRNA knockdown of ERBB4 or treatment with ERBB inhibitor.